GlassScriptPhysician profile
Lynn A Toaz
NPI 1912924895
$1,406.93
in general payments reported to CMS, 2019-2025
22 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.20 · 2020: $100 · 2021: $112 · 2022: $437 · 2023: $361 · 2024: $213 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $718.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $374.22 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $169.17 | 2019-2025 | |
| Abbvie INC. | $166.64 | 2021-2025 | Vraylar |
| Dexcom, INC. | $105.79 | 2021-2023 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $101.79 | 2020-2023 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.02 | 2022-2025 | Jardiance |
| Glaxosmithkline, LLC. | $67.14 | 2020-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $66.48 | 2021-2025 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $51.18 | 2020-2023 | Rexulti |
| Corium, LLC | $24.14 | 2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $21.80 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.13 | 2020 | |
| Intuitive Surgical, INC. | $21.09 | 2024 | |
| Merck Sharp & Dohme LLC | $19.56 | 2023 | Vaxelis, Gardasil 9, Pneumovax 23 |
| Exact Sciences Corporation | $18.10 | 2023 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $17.92 | 2022 | |
| Alkermes, INC. | $17.33 | 2022 | |
| Astellas Pharma US INC | $16.57 | 2024 | Veozah |
| Verona Pharma, INC. | $15.41 | 2025 | Ohtuvayre |
| Cranial Technologies, INC | $15.38 | 2024 | Doc Band |
| Amgen INC. | $14.07 | 2023 | Evenity, Prolia |
| Daiichi Sankyo INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Toaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.